A study published in Chest outlines a new data-driven algorithm that can identify patients at increased risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The algorithm also quantifies carbapenem resistance.
[maxbutton id=”1″ url=”http://info.respiratory-therapy.com/regform” text=”SUBSCRIBE TO NEWS” ]
Results of this study suggested that infection with carbapenem-resistant organisms significantly contributed to increased hospital costs and length of stay.
This retrospective cohort study included 8969 individuals with HAP (50.8%) and VAP (48.2%) from the Premier Research database (2009-2016).
Carbapenem resistance was found in 11.8% of participants. Compared with participants whose samples showed carbapenem-susceptible organisms, carbapenem resistance was associated with patients who were admitted from an extended-care facility.
